Literature DB >> 26900624

Rabies post-exposure prophylaxis for a child with severe allergic reaction to rabies vaccine.

Yuan Fang1, Man-Qing Liu2, Li Chen3, Zheng-Gang Zhu2, Ze-Rong Zhu2, Quan Hu2.   

Abstract

Most adverse events (AEs) during the immunization of rabies vaccine were slight, there was little information about the allergic reaction induced by rabies vaccines and had to stop or change the immunization program. Here, we reported a case that a 4-year-old boy had category II exposure to rabies and showed severe allergic reaction after being immunized with lyophilized purified vero cell rabies vaccine (PVRV). After the anti-allergy therapy with hormone, allergy testing indicated medium allergy to egg and milk, and implied the allergic reaction most likely associated with animal-sourced gelatin in lyophilized PVRV. Therefore, a new immunization program with liquid PVRV without stabilizers under the Zegrab regimen (2-1-1) was enrolled at day 7 post-exposure. Although lower than the levels of normal <5 -year population at day 14 and 45, the neutralizing antibody (RVNA) titers of this boy showed adequate protective antibody (≥ 0.5 IU/ml), even after 365 d post-immunization. This study not only highlighted the importance of several types of rabies vaccines co-existing in the market, but also implied the necessary for doctors to fully understand the allergies history of patients prior to immunize rabies vaccine.

Entities:  

Keywords:  allergic reaction; neutralizing antibody (RVNA) titer; purified chick embryo cell vaccine (PCECV); purified vero cell rabies vaccine (PVRV); rabies virus neutralizing antibody (RVNA)

Mesh:

Substances:

Year:  2016        PMID: 26900624      PMCID: PMC4964825          DOI: 10.1080/21645515.2016.1143158

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  10 in total

1.  Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin.

Authors:  M Sakaguchi; T Nakayama; H Fujita; M Toda; S Inouye
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

2.  [A study on efficacy of rabies vaccine prepared by primary hamster kidney cells in Guangxi].

Authors:  T Wu; Y Lu; X Ge
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  1998-07

3.  Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG.

Authors:  Jun Peng; Li Chen; Zheng-Gang Zhu; Ze-Rong Zhu; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Side effects and risks of rabies vaccine.

Authors:  Olivier Sabella
Journal:  Can Fam Physician       Date:  2009-05       Impact factor: 3.275

5.  Production and evaluation of a chromatographically purified Vero cell rabies vaccine (PVRV) in China using microcarrier technology.

Authors:  Pengcheng Yu; Ying Huang; Yibin Zhang; Qing Tang; Guodong Liang
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

6.  Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China.

Authors:  Quan Hu; Man-Qing Liu; Zheng-Gang Zhu; Ze-Rong Zhu; Sha Lu
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

7.  Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India.

Authors:  Mysore Kalappa Sudarshan; Doddabele Hanumanthaiah Ashwath Narayana; Shampur Narayan Madhusudana; Ramesh Holla; Belludi Yajaman Ashwin; Bilagumba Gangaboraiah; Haradanahalli S Ravish
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

8.  Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.

Authors:  Susan E Manning; Charles E Rupprecht; Daniel Fishbein; Cathleen A Hanlon; Boonlert Lumlertdacha; Marta Guerra; Martin I Meltzer; Praveen Dhankhar; Sagar A Vaidya; Suzanne R Jenkins; Benjamin Sun; Harry F Hull
Journal:  MMWR Recomm Rep       Date:  2008-05-23

9.  Rabies: 100 per cent fatal, 100 per cent preventable.

Authors:  B Abela-Ridder
Journal:  Vet Rec       Date:  2015-08-08       Impact factor: 2.695

10.  Comparison of safety and immunogenicity of PVRV and PCECV immunized in patients with WHO category II animal exposure: a study based on different age groups.

Authors:  Yuan Fang; Li Chen; Man-Qing Liu; Zheng-Gang Zhu; Ze-Rong Zhu; Quan Hu
Journal:  PLoS Negl Trop Dis       Date:  2014-12-18
  10 in total
  4 in total

1.  Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination.

Authors:  Zheng-Gang Zhu; Yi Zheng; Sha Lu; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2018-06-29       Impact factor: 3.452

2.  Severe multiple rabid dog bite injuries in a child in central China: Continuous 10-year observation and analysis on this case.

Authors:  Zhenggang Zhu; Shichun Huang; Sha Lu; Man Zhang; Shengli Meng; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

3.  Analysis on the risks of severe adverse events in rabies post-exposure prophylaxis and appropriate decision-making procedure.

Authors:  Shichun Huang; Zhenggang Zhu; Li Cai; Zerong Zhu; Man Zhang; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2018-10-26       Impact factor: 3.452

4.  Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial.

Authors:  Lei Zhang; Shichun Huang; Li Cai; Zhenggang Zhu; Jian Chen; Sha Lu; Zerong Zhu; Man Zhang; Yuan Fang; Quan Hu
Journal:  Hum Vaccin Immunother       Date:  2021-02-25       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.